Merck's Lipfendra FDA Approval Recap, Plus $0.85 Dividend and Gardasil Scrutiny
MRK sits 70% above its 52-week low of $77.53.
Summary
The weekly recap highlights the July 17 FDA approval of Lipfendra, Merck's first oral PCSK9 inhibitor for high LDL cholesterol, a significant commercial milestone. It also notes the declaration of a $0.85 quarterly dividend for Q4 2026, payable October 7 to shareholders of record September 15, reinforcing the company's commitment to shareholder returns. Additionally, U.S. senators have asked Health Secretary Robert F. Kennedy Jr. to disclose any family financial ties to Merck related to a $50 million Gardasil litigation settlement, introducing a potential political overhang. The Lipfendra approval was previously reported, but the dividend and the senators' request are new developments that could influence near-term sentiment.
At the time of this announcement, MRK was trading at $131.67 on NYSE in the Life Sciences sector, with a market capitalization of approximately $321.6B. The 52-week trading range was $77.53 to $135.05. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.